GPP
ADVM

Great Point Partners’s Adverum Biotechnologies ADVM Stock Holding History

Great Point Partners’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-55,012
Closed -$1.74M – 36
2016
Q2 		$1.74M Sell
55,012
-74,530
-58% -$3.37M 0.5% 28
2016
Q1 		$6.7M Buy
+129,542
New +$7.23M 2.4% 15

Other funds holding ADVM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Great Point Partners's ADVM Position: Q3 2016 in Review

Great Point Partners sold out of Adverum Biotechnologies (ADVM) in Q3 2016, closing a stake of 55,012 shares — an estimated $1.74M sold.

Great Point Partners first reported a position in ADVM in Q1 2016 and held it in 2 quarters. The position peaked at $6.7M in Q1 2016. 76 funds tracked by Wall St. Rank hold ADVM as of Q3 2016.

  • Great Point Partners reported no remaining Adverum Biotechnologies position as of Q3 2016 after selling out during the quarter.
  • Great Point Partners sold 55,012 Adverum Biotechnologies shares in Q3 2016, an estimated $1.74M.
  • Great Point Partners first reported a position in Adverum Biotechnologies in Q1 2016 and held it in 2 quarters.
  • Great Point Partners's Adverum Biotechnologies position peaked at $6.7M in Q1 2016.
  • 76 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q3 2016.

Based on Great Point Partners's 13F filing for Q3 2016, filed 14 Nov 2016.